Literature DB >> 17136403

[Molecular imaging with new PET tracers].

A J Beer1, M Schwaiger.   

Abstract

In the recent years, positron emission tomography (PET) has gained more and more importance, especially in oncology for primary staging, as well as for response evaluation. The glucose analogon (18)F-FDG is the most widely used tracer up to now. In this paper, we review the applications of newly developed, more specific PET tracers. These tracers allow for imaging of a variety of biological processes, such as hypoxia and proliferation. The expression of different receptors can be visualized, like the somatostatin receptor 2 and the integrin alphavbeta3. Moreover, gene expression can be imaged as well. While most of these approaches are currently in the first phases of clinical evaluation, imaging of hypoxia and proliferation might be integrated into the daily routine in the near future.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17136403     DOI: 10.1007/s00117-006-1448-6

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  58 in total

1.  Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.

Authors:  R Haubner; H J Wester; U Reuning; R Senekowitsch-Schmidtke; B Diefenbach; H Kessler; G Stöcklin; M Schwaiger
Journal:  J Nucl Med       Date:  1999-06       Impact factor: 10.057

2.  Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.

Authors:  Morand Piert; Hans-Jürgen Machulla; Maria Picchio; Gerald Reischl; Sybille Ziegler; Piyush Kumar; Hans-Jürgen Wester; Roswitha Beck; Alexander J B McEwan; Leonard I Wiebe; Markus Schwaiger
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

3.  Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen.

Authors:  Laura P Stabile; Autumn L Gaither Davis; Christopher T Gubish; Toni M Hopkins; James D Luketich; Neil Christie; Sydney Finkelstein; Jill M Siegfried
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

4.  PET imaging with [11C]methyl- L-methionine for therapy monitoring in patients with rectal cancer.

Authors:  Hinrich Wieder; Katja Ott; Frank Zimmermann; Hjalmar Nekarda; Jens Stollfuss; Petra Watzlowik; Jörg-Rüdiger Siewert; Ulrich Fink; Karen Becker; Markus Schwaiger; Wolfgang Andreas Weber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03-13       Impact factor: 9.236

5.  Quantification of [18F]diprenorphine kinetics in the human brain with compartmental and non-compartmental modeling approaches.

Authors:  Mary E Spilker; Till Sprenger; Michael Valet; Gjermund Henriksen; Klaus Wagner; Hans-J Wester; Thomas R Toelle; Henning Boecker
Journal:  Neuroimage       Date:  2004-08       Impact factor: 6.556

6.  Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice.

Authors:  Masahiro Sugiyama; Harumi Sakahara; Kengo Sato; Norihiro Harada; Dai Fukumoto; Takeharu Kakiuchi; Toru Hirano; Eiji Kohno; Hideo Tsukada
Journal:  J Nucl Med       Date:  2004-10       Impact factor: 10.057

7.  Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy.

Authors:  Ambros J Beer; Hinrich A Wieder; Florian Lordick; Katja Ott; Michael Fischer; Karen Becker; Jens Stollfuss; Ernst J Rummeny
Journal:  Radiology       Date:  2006-03-16       Impact factor: 11.105

8.  First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography.

Authors:  Margret Schottelius; Thorsten Poethko; Michael Herz; Jean-Claude Reubi; Horst Kessler; Markus Schwaiger; Hans-Jürgen Wester
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

9.  68Ga-labeled oligonucleotides for in vivo imaging with PET.

Authors:  Anne Roivainen; Tuula Tolvanen; Satu Salomäki; Gabor Lendvai; Irina Velikyan; Petri Numminen; Maria Välilä; Hannu Sipilä; Mats Bergström; Pirkko Härkönen; Harri Lönnberg; Bengt Långström
Journal:  J Nucl Med       Date:  2004-02       Impact factor: 10.057

Review 10.  Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects: applications to breast cancer.

Authors:  F Berger; S S Gambhir
Journal:  Breast Cancer Res       Date:  2000-12-11       Impact factor: 6.466

View more
  2 in total

Review 1.  Radiolabelled RGD peptides for imaging and therapy.

Authors:  F C Gaertner; H Kessler; H-J Wester; M Schwaiger; A J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

2.  Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature.

Authors:  Oliver Schnell; Bjarne Krebs; Erika Wagner; Alexander Romagna; Ambros J Beer; Stefan J Grau; Niklas Thon; Claudia Goetz; Hans A Kretzschmar; Jörg-Christian Tonn; Roland H Goldbrunner
Journal:  Brain Pathol       Date:  2008-04-02       Impact factor: 6.508

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.